<DOC>
	<DOCNO>NCT02919046</DOCNO>
	<brief_summary>This single-arm , multicenter clinical study treat patient relapse refractory neuroblastoma infusion patient 's T cell genetically modify express chimeric antigen receptor ( CAR ) bind tumour cell modify express GD2 protein cell surface . The study determine modify T cell help body 's immune system eliminate tumour cell .The trial also study safety treatment CAR-T , long CAR-T cell stay patient 's body impact treatment survival .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety With CAR-T Relapsed Refractory Neuroblastoma Children</brief_title>
	<detailed_description>This single-arm , multicenter clinical study evaluate efficacy safety chimeric antigen receptor T cell immunotherapy ( CAR-T ) treatment relapse refractory neuroblastoma child . The study conduct use phaseⅠ/Ⅱdesign study follow sequential phase : part A ( screen , leukapheresis , cell product preparation cytoreductive chemotherapy ) part B ( treatment follow-up ) . follow-up period participant approximately 35 month final CAR-T infusion . The total duration study expect approximately 3 year . A total 22 patient may enrol period 3 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>1 . Up diagnostic criterion relapse refractory neuroblastoma highrisk patients，including : Relapsed neuroblastoma : Children diagnose neuroblastoma standard treatment remission , present lesion reach complete remission surgery . Refractory neuroblastoma : ① Untreated patient reach completes remission 4 course chemotherapy accordance standard regimen reach complete remission surgery . ② Highrisk patient : Who cell genetic variation , MYCN amplification bone marrow metastasis . 2 . Relapsed Refractory Neuroblastoma : Target , expression may intervene , discover Immunohistochemistry select ( GD2 + ) ( 50 % tumor cell least 2+ , adopt antiGD2mAb14G2a ) . 3 . Age : 1~14 year old age time enrollment , male female . 4 . Physical condition good : ECOG score reach 0 2 point . 5 . Body weight great equal 10 kg . 6 . White blood cell count acuity≥ 1.0 x10^9 / L. 7 . Estimated survival time &gt; 90 day . 8 . Voluntary participation , good compliance , cooperate experimental observation sign informed consent form . 1 . Positive pregnancy test . 2 . Uncontrolled infection . 3 . HIV infection , hepatitis B C activity period . 4 . Patients need longterm immunosuppressive therapy ( Such allergy , autoimmune disease , GVHD , etc . ) 5 . Combined activity central nervous system malignant tumor invasion . 6 . Abnormal coagulation function , patient severe thrombosis . 7 . Organ failure 1 . Heart：class Ⅱ . 2 . Liver：class Ⅱ ( Refer Classification Wuhan Conference ( 1983 ) ) . 3 . Kidney : The second stage renal insufficiency . 4 . Lung : class Ⅱdecreased slightly . 5 . Brain : The central nervous system transfer active lesion . 8 . Patients participate clinical trial clinical trial past 30 day . 9 . The researcher believe patient suitable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>neuroblastoma</keyword>
	<keyword>CAR-T</keyword>
</DOC>